A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.

119-s4327 — A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.. Sponsored by Sen. Cotton, Tom [R-AR]. Introduced 2026-04-16. Senate bill. 119th Congress. Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

119-s4327 119th Congress Senate

Bill Activity

House
Introduced
2026-04-16
Introduced in Senate
Committee
2026-04-16
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Senate
Referred to Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsor
Sen. Cotton, Tom [R-AR] (R), AR
Introduced
2026-04-16
Committees
Health, Education, Labor, and Pensions Committee
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

No roll-call vote data available for this bill.

Explore This Bill

Investigate this bill → AI summary, roll-call breakdown, and full bill analysis